DALLAS, Feb. 3, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug and diagnostics company Compugen Ltd. (Nasdaq:CGEN) . The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/CGEN
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Compugen Ltd. (CGEN) is a biotechnology discovery company focused on therapeutic and diagnostic products. The Company's powerful predictive models and discovery engines enable the discovery of numerous potential therapeutics and diagnostic biomarkers. CGEN develops products using computer-based discovery platforms, as well as through analyzing DNA or RNA sequences, gene expression data, protein network data, data related to drugs in development, and drugs already being commercialized. To date, the Company's discovery efforts have focused mainly on cancer, cardiovascular and immune-related diseases.
Message Board Search for CGEN: http://www.boardcentral.com/boards/CGEN
In the report, the analyst notes:
“CGEN's increasing inventory of powerful and proprietary discovery platforms is enabling the predictive discovery – field after field – of numerous therapeutic and diagnostic product candidates. CGEN co-CEO Martin Gerstel has previously stated that the industry interest and collaboration opportunities that they are now seeing for the Company exist solely due to the broadly applicable drug and biomarker discovery capability that has been created at CGEN during the past decade.
“CGEN yesterday announced the discovery and experimental validation of CGEN-15001 for the treatment of autoimmune disorders, which collectively affects an estimated 25 million people in the United States ... Dr. Zurit Levine stated that, in addition to providing the Company with a very attractive product candidate, the predictive discovery and experimental validation of a previously unknown member of this extensively researched protein family represents a major milestone in the transition from experimentally based therapeutic discovery to in silico prediction and selection.”
To read the entire report visit: http://www.stockpreacher.com/n/CGEN
See what investors are saying about CGEN at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Neither StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.